Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
Summary not available.
Summary not available.
MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the release of its first quarter 2023 financial results on May 11, 2023. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide corporate updates. The conference call will be accessible via phone and online, with dedicated dial-in numbers for participants in the USA and Canada. MiNK is advancing its pipeline of native and engineered iNKT programs aimed at treating cancer and other immune-mediated diseases, emphasizing scalable manufacturing for off-the-shelf delivery.
MiNK Therapeutics (Nasdaq: INKT) presented promising results at the AACR annual meeting for its iNKT cell therapy, agenT-797, showing effectiveness against refractory solid tumors. In a phase 1/2 trial involving heavily pretreated patients, significant tumor shrinkage of over 42% was observed in a patient with gastric cancer, maintaining response for over 9 months. The therapy, administered without toxic lymphodepletion, remained detectable for about 8 weeks, promoting immune cell infiltration into tumors. Following these results, MiNK plans to expand trials, combining agenT-797 with established therapies in additional cancer types, furthering its commitment to advancing cancer treatment options.
Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.
MiNK Therapeutics reported its financial results for Q4 and full year 2022, highlighting key advancements in their iNKT cell therapy programs. The company ended 2022 with a cash balance of $19.6 million, down from $38.9 million in 2021. Net loss for Q4 2022 was $7.8 million, or $0.23 per share, showing an increase from $5.8 million in Q4 2021. MiNK's therapy, AgenT-797, demonstrated clinical activity in solid tumors and will feature at the upcoming AACR Annual Meeting. The firm is advancing plans for combination studies and manufacturing capabilities to enhance production efficiency.
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced an upcoming presentation of updated clinical data on its allo-iNKT cell therapy, agenT-797, scheduled for the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. The presentation, titled 'Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs),' will be conducted by Dr. Benedito Carneiro on April 18, 2023. MiNK is focused on developing innovative iNKT cell therapies for cancer treatment, leveraging a scalable manufacturing platform. This update could impact investor sentiment based on the therapy's progress in advanced solid tumors.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced the release of its fourth quarter and full year 2022 financial results on March 21, 2023, before market open. The leadership team will conduct a conference call and webcast at 8:30 a.m. ET the same day to discuss these results and provide a corporate update. MiNK is focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, utilizing a scalable manufacturing platform. For more details, investors can join the live webcast or access it later through the company’s website.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28 at 9:00 AM ET. The chat will focus on MiNK's pioneering work in allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases. Interested participants can access the live chat here, with a replay available on MiNK's website thereafter.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. The live chat can be accessed via B. Riley's website, with a replay available afterward on MiNK's Events and Presentations page. The conference, taking place on January 18-19, will showcase over 30 healthcare companies focusing on innovations in cancer treatment, featuring discussions by key opinion leaders in the field.